Predictability of Capillary Blood Spot Toward Venous Whole Blood Sampling for Therapeutic Drug Monitoring of Tacrolimus in Solid Organ Transplant Recipients.
Journal
European journal of drug metabolism and pharmacokinetics
ISSN: 2107-0180
Titre abrégé: Eur J Drug Metab Pharmacokinet
Pays: France
ID NLM: 7608491
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
pubmed:
23
4
2019
medline:
22
4
2020
entrez:
23
4
2019
Statut:
ppublish
Résumé
Therapeutic drug monitoring (TDM) of tacrolimus in whole blood obtained from venipuncture is routinely practiced. Dried blood spotting (DBS) may act as a suitable alternative for tacrolimus TDM due to relative ease of sampling and processing. The objective of this literature review was to provide a critical evaluation on the feasibility (i.e., accuracy and precision) of DBS for predicting tacrolimus whole blood concentrations in solid organ transplant recipients. A comprehensive systematic literature search using PubMed, Scopus, EMBASE, and Google Scholar was conducted. The primary objective was to extract the bias and precision data from the identified papers. In addition, the collection, storage, and analysis protocols were also summarized. Both adult and pediatric data were included. The reported bias data (primarily based on individual concentrations) in the majority of studies were within acceptable limits (< 15%). However, the precision data were not consistently reported. The area under the concentration-time curve of tacrolimus derived from DBS appeared to be a better predictor of whole blood compared to single concentrations based on a limited number of studies. No apparent differences in prediction were observed between pediatric and adult patients. Small sample sizes and the lack of complete description of the study population were common limitations. DBS is a promising approach for tacrolimus TDM. However, in order for DBS to become a useful substitute for tacrolimus whole blood monitoring in solid organ transplant patients, further systematic studies with sufficient power and comprehensive prediction error analyses are required.
Identifiants
pubmed: 31006833
doi: 10.1007/s13318-019-00553-z
pii: 10.1007/s13318-019-00553-z
doi:
Substances chimiques
Immunosuppressive Agents
0
Tacrolimus
WM0HAQ4WNM
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
729-741Références
J Pharm Biomed Anal. 2007 Jul 27;44(3):658-64
pubmed: 17184953
Clin Pharmacokinet. 2014 Nov;53(11):961-73
pubmed: 25204403
Mass Spectrom Rev. 2016 May-Jun;35(3):361-438
pubmed: 25252132
Am J Transplant. 2019 May;19(5):1410-1420
pubmed: 30506623
Br J Nurs. 2017 Jul 27;26(14):S4-S10
pubmed: 28745951
Ther Drug Monit. 2017 Aug;39(4):412-421
pubmed: 28700522
Ann Clin Biochem. 2014 Jan;51(Pt 1):106-9
pubmed: 23939194
J Pharmacokinet Biopharm. 1981 Aug;9(4):503-12
pubmed: 7310648
Transplantation. 2007 Jan 27;83(2):237-8
pubmed: 17264824
Transpl Int. 2008 Feb;21(2):140-5
pubmed: 17944802
Eur J Drug Metab Pharmacokinet. 2019 Jun;44(3):409-422
pubmed: 30377942
Expert Opin Drug Metab Toxicol. 2017 Dec;13(12):1225-1236
pubmed: 29084469
J Infus Nurs. 2016 Sep-Oct;39(5):273-9
pubmed: 27598066
Pediatr Transplant. 2017 Sep;21(6):null
pubmed: 28635157
Transplantation. 2017 Jul;101(7):1727-1733
pubmed: 27906832
J Chromatogr B Analyt Technol Biomed Life Sci. 2013 May 1;926:54-61
pubmed: 23548676
Pediatr Transplant. 2015 Feb;19(1):101-6
pubmed: 25414084
Clin Chim Acta. 2016 Feb 15;454:1-5
pubmed: 26721314
Br J Clin Pharmacol. 2018 Dec;84(12):2889-2902
pubmed: 30176064
J Pharm Biomed Anal. 2016 Oct 25;130:231-243
pubmed: 27390013